The systemic inflammatory response syndrome is predictive of renal dysfunction in patients with non-paracetamol-induced acute liver failure

Gut

Volumn 58, Issue 3, 2009, Pages 443-449

  Leithead, J A ^a,b   Ferguson, J W ^a   Bates, C M ^a   Davidson, J S ^a   Lee, A ^a   Bathgate, A J ^a   Hayes, P C ^a   Simpson, K J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; PARACETAMOL;

ADULT; ALCOHOL LIVER DISEASE; ARTICLE; AUTOIMMUNE DISEASE; BUDD CHIARI SYNDROME; CREATININE BLOOD LEVEL; DRUG OVERDOSE; FEMALE; HEART RATE; HEPATITIS; HEPATITIS A; HEPATITIS B; HOSPITALIZATION; HUMAN; HYPOTENSION; HYPOTHERMIA; INFECTION; KIDNEY INJURY; LEUKOCYTE COUNT; LIVER FAILURE; LIVER FATTY DEGENERATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PATHOGENICITY; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SERODIAGNOSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; WILSON DISEASE;

ADULT; FEMALE; HUMANS; KIDNEY FAILURE, ACUTE; LIVER FAILURE, ACUTE; MALE; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 61649114283     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2008.154120     Document Type: Article

References (59)

1. Wilkinson SP, Moodie H, Arroyo VA, et al. Frequency of renal impairment in paracetamol overdose compared with other causes of acute liver damage. J Clin Pathol 1977;30:141-3.
2. Ring-Larsen H, Pallazo U. Renal failure in fulminant hepatic failure and terminal cirrhosis: a comparison between incidence, types and prognosis. Gut 1981;22:585-91.
3. O'Grady JG, Alexander GJ, Hayllar KM, et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-45.
4. Salerno F, Gerbes A, Gines P, et al. Diagnosis, prevention, and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56:1310-8.
5. O'Grady J. Clinical disorders of renal function in acute liver failure. In: Gines P, Arroyo V, Rodes J, et al, eds. Ascites and renal dysfunction in liver disease. Oxford: Blackwell Publishing, 2005:383-93.
6. Trewby PN, Williams R. Pathophysiology of hypotension in patients with fulminant liver failure. Gut 1977;18:1021-6.
7. Guarner F, Hughes RD, Gimson AE, et al. Renal function in fulminant hepatic failure. Gut 1987;28:1643-7.
8. Makin AJ, Hughes RD, Williams R. Systemic and hepatic hemodynamic changes in acute liver injury. A J Physiol 1997;272:G617-25.
9. Navasa M, Garcia-Pagan JC, Bosch J, et al. Portal hypertension in acute liver failure. Gut 1992;33:965-68.
10. Guevara M, Gines P, Bandi JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998;28:416-22.
11. Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005;42:439-47.
12. Ytrebo LM, Sens S, Rose C, et al. Systemic and regional hemodynamics in pigs with acute liver failure and the effect of albumin dialysis. Scand J Gastroenterol 2006;41:1350-60.
13. Ytrebo LM, Ekse S, Sen S, et al. Contractile response of femoral arteries in pigs with acute liver failure. Scand J Gastroenterol 2004;10:1000-4.
14. Fernandez-Seara J, Prieto J, Quiroga J, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 1989;97:1304- 12.
15. Maroto A, Gines P, Arroyo V, et al. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology 1993;17:788-93.
16. Pickers P, Dorresteijn MJ, Bouw M, et al. In vivo evidence for nitric oxide-mediated calcium-activated potassium-channel activation during human endotoxaemia. Circulation 2006;114:414-21.
17. Wan L, Bagshaw S, Langenberg C, et al. Pathophysiology of septic acute kidney injury: what do we really know? Crit Care Med 2008;36(4 Suppl):S198-203.
18. Rolando N, Wade J, Davalos M, et al. The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000;32:734-9.
19. Vaquero J, Polson J, Chung C, et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology 2003;125:755-64.
20. Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med 2004;351:159-69.
21. Moore K. Renal failure in acute liver failure. Eur J Gastroenterol Hepatol 1999;11:967-75.
22. Pernambuco JR, Langley PG, Hughes RD, et al. Activation of the fibrinolytic system in patients with fulminant liver failure. Hepatology 1993;18:1350-6.
23. Blakely P, McDonald BR. Acute renal failure due to paracetamol ingestion: a case report and review of the literature. J Am Soc Nephrol 1995;6:48-53.
24. Blantz RC. Paracetamol: acute and chronic effects on renal function. Am J Kidney Dis 1996;28(1 Suppl 1):S3-6.
25. Boutis K, Shannon M. Nephrotoxicity after acute severe paracetamol poisoning in adolescents. J Toxicol Clin Toxicol 2001;39:441-5.
26. Trey C. Davidson CS. The management of fulminant hepatic failure. In: Popper H, Schaffner F, eds. Progress in liver failure. New York: Grune and Stratton, 1970:292-8.
27. Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204- 12.
28. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
29. International Centre for Alcohol Policies. Report 14: International drinking guidelines, December 2003. http://www.icap.org
30. Schmidt LE, Larsen FS. Prognostic implications of hyperlactinemia, multiple organ failure, and systemic inflammatory response syndrome in patients with acetaminophen-induced acute liver failure. Crit Care Med 2006;34:337-43.
31. Bone R. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 1996;24:163-72.
32. Sekiyama KD, Yoshiba M, Thomson AW. Circulating proinflammatory cytokines (IL-1 beta, TNF-alpha, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis. Clin Exp Immunol 1994;98:71-7.
33. Hughes RD, Nicolaou N, Langley PG, et al. Plasma cytokine levels and coagulation and complement activation during use of the extracorporeal liver assist device in acute liver failure. Artif Organs 1998;22:854-8.
34. Tokushige K, Yamaguchi N, Ikeda I, et al. Significance of soluble TNF receptor-1 in acute-type fulminant hepatitis. Am J Gastroenterol 2000;95:2040-6.
35. Nagaki M, Iwai H, Ohnishi H, et al. High levels of serum interleukin-10 and tumour necrosis factor-alpha are associated with fatality in fulminant hepatitis. J Infect Dis 2000;182:1103-8.
36. Wilkinson SP, Arroyo V, Gazzard BG, et al. Relation of renal impairment and haemorrhagic diathesis to endotoxaemia in fulminant hepatic failure. Lancet 1974;1:521-4.
37. Boermeester MA, Houdijk A, Meyer S, et al. Liver failure induces a systemic inflammatory response. Am J Pathol 1995;147:1428-40.
38. Bonegio R, Lieberthal W. Role of apoptosis in the pathogenesis of acute renal failure. Curr Opin Nephrol Hypertens 2002;11:301-8.
39. Vila E, Salaices M. Cytokines and vascular reactivity in resistance arteries. Am J Physiol Heart Circ Physiol 2005;288: H1016-21.
40. Sheron N, Goka J, Wendon J, et al. Plasma cytokine levels in fulminant hepatic failure: associations with multiple organ failure [abstract]. J Hepatol 1991;13(Suppl):S71.
41. Thabut D, Massard J, Gangloff A, et al. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology 2007;46:1872-82.
42. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-9.
43. Such J, Frances R, Munoz C, et al. Detection and identification of bacterial DNA in patients with cirrhosis and culture negative, nonneutrocytic ascites. Hepatology 2002;36:135-41.
44. Frances R, Benlloch S, Zapater P, et al. A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites. Hepatology 2004;39:484-91.
45. Burke GW, Cirroco R, Roth D, et al. Activated cytokine pattern in hepatorenal syndrome: fall in levels after successful orthoptic liver transplantation. Transplant Proc 1993;25:1876-7.
46. Navasa M, Follo A, Filella X, et al. Tumour necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 1998;27:1227-32.
47. Genesca J, Gonzalez A, Segura R, et al. Interleukin-6, nitric oxide, and the clinical and haemodynamic alterations of patients with liver cirrhosis. Am J Gastroenterol 1999;94:169-77.
48. Albillos A, de la Hera A, Gonzalez M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003;37:208-17.
49. Fernandez J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007;133:818-24.
50. Tsai MH, Iwakiri Y, Cadelina G, et al. Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive rats. Gastroenterology 2003;125:1452-61.
51. Stuber F. Effects of genomic polymorphisms on the course of sepsis: is there a concept for gene therapy? J Am Soc Nephrol 2001;12:S60-4.
52. Mitchell JR, McMurtry RJ, Statham CN, et al. Molecular basis for several drug-induced nephropathies. Am J Med 1977;62:518-26.
53. Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.
54. Polson J, Lee WM; American Association for the Study of Liver Disease. AASLD position paper: the management of acute liver failure. Hepatology 2005;41:1179-97.
55. Ronco C, Bonello M, Bordoni V, et al. Extracorporeal therapies in non-renal disease: treatment of sepsis and the peak concentration hypothesis. Blood Purif 2004;22:164-74.
56. Sen S, Mookerjee RP, Cheshire LM, et al. Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. J Hepatol 2005;43:142-8.
57. Sen S, Mookerjee RP, Davies NA, et al. Review article: the molecular adsorbents recirculating system (MARS) in liver failure. Aliment Pharmacol Ther 2002;16(Suppl 5):32-8.
58. Wang W, Zolty E, Falk S, et al. Pentoxifylline protects against endotoxin-induced acute renal failure in mice. Am J Physiol Renal Physiol 2006;291:F1090-5.
59. Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:1637-48.